Overview

TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen

Status:
Completed
Trial end date:
2003-02-01
Target enrollment:
Participant gender:
Summary
Primary objective: To determine the rate of confirmed treatment failure and relapse with an intermittent rifabutin-based regimen for the treatment of isoniazid and rifamycin-susceptible HIV-related tuberculosis (TB).
Phase:
N/A
Details
Lead Sponsor:
Centers for Disease Control and Prevention
Collaborators:
US Department of Veterans Affairs
VA Office of Research and Development
Treatments:
Rifabutin